Femasys is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies. Its reproductive health portfolio includes FemVue®, a commercially available product for fallopian tube assessment by ultrasound, FemCath™, an intrauterine catheter for selective evaluation of the tubes and FemaSeed™, the first and only approach that delivers sperm directly to the fallopian tube that is now in a pivotal trial.